Marketing & Communications
Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.
The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.
FDA's latest guidance says it is ok to reduce the amount of risk information in print ads, Google amplifies the health information it will serve up with searches and HBO's John Oliver takes on pharmaceutical marketing.
A look at the content that grabbed most reader interest over the past year.
BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.
The driver on NASCAR and other racing circuits will help challenge consumers to improve their health habits.
A trio of doctors make a case for putting limits on digital promotions, including those in EHRs and through social networks.
The decades-old drug is winning prescriptions through marketing, but has a free-pass when it comes to clinical trial data.
Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.
Regulatory Focus reports that the regulator has issued a Warning Letter to AB Science for marketing its canine tumor drug Kinavet for unapproved, off-label uses.
GlaxoSmithKline dismissed a marketer over its approach to clinical trial recruiting.
The drugmaker is pulling its US marketing application for the anemia drug.
Researchers found that limiting sales rep access and interactions reduces off-label prescriptions for the previously detailed drugs, while also upping off-label prescriptions of the drugs that had not been promoted.
The advertising watchdog gave drugmaker Alvogen 15 days to make amends.
Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.
The Arkansas Supreme Court's decision puts $1.2 billion back into J&J's coffers.
The company unveiled the mix-and-match marketing management tool at the Eye for Pharma conference in Barcelona.
The drugmaker's annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.
The US Attorney's Office for the Southern District of New York is examining how Teva has marketed MS drug Copaxone and Parkinson's medication Azilect since 2006.
Movable Ink reports that 65% of Q4 emails were opened on a tablet or smartphone.
A court in India ruled biosimilar drug makers will not be able to cite the drug's name, efficacy or safety profile in its marketing.
A survey of UK-based general practitioners shows industry websites are not a go-to source for information. Reps did not fare well, either.
An appeals court says J&J does not have to pay $257.7 million.
Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.
The drugmaker announced Friday that the DOJ wants documents regarding sales and marketing of Juxtapid, its drug for an ultra-rare lipid disorder.
Lobbying groups say the ad tax draft proposal could wreak havoc throughout the ad industry and its partners, such as publishers and broadcasters, if it were to go through.
The Gray Lady surveys the landscape of attention deficit disorder marketing.
The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.
The government division is scrutinizing marketing information for three drugs.
The marketing watchdog's untitled letter says a direct mailer failed to disclose "material facts" from the warnings and precautions section of the PI.
The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.